Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel

This study is collecting immune biomarkers from patients with head and neck cancers (throat, voice box, or mouth) who cannot receive cisplatin (the standard chemotherapy) and are instead being treated with a different chemotherapy drug (docetaxel) combined with radiation. The goal is to predict who will respond best to this approach. **You may be eligible if...** - You have squamous cell carcinoma of the oropharynx (throat), larynx (voice box), or oral cavity (mouth) - You are receiving definitive or post-surgery chemoradiotherapy - You are not a suitable candidate for cisplatin due to: poor performance status (ECOG 2), significant hearing loss, reduced kidney function (creatinine clearance ≤50 mL/min), heart problems, or other organ issues **You may NOT be eligible if...** - You are fit enough to receive cisplatin chemotherapy - Your cancer type is not squamous cell carcinoma of the listed head and neck locations - You are unwilling to participate or cannot provide informed consent Talk to your doctor to see if this trial is right for you.